Stay updated on Savolitinib Combo in EGFRm+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page.

Latest updates to the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe page revision was updated from v3.6.2 to v3.6.3, indicating a minor update to the page version.SummaryDifference0.0%

- Check18 days agoChange DetectedThe page now displays Revision: v3.6.2, replacing the prior Revision: v3.6.0, indicating an update to the page’s revision history.SummaryDifference0.0%

- Check32 days agoChange DetectedNew user-guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and a header for Intervention/Treatment appears in the study details. A recruitment status note 'No longer looking for participants' was added and the page revision is labeled v3.6.0.SummaryDifference0.4%

- Check39 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, signaling a minor update or correction to the page’s documentation or layout rather than a change to the study details. No substantive study information appears to have been modified.SummaryDifference0.0%

- Check60 days agoChange DetectedA new page revision tag 'Revision: v3.5.4' was added and the previous 'Revision: v3.5.3' tag was removed, signaling a version update of the page without altering the study details.SummaryDifference0.0%

- Check68 days agoChange DetectedThe Taiwan site entry with postal code 333 was updated to Taoyuan City, Taiwan, 333. The previous Taoyuan, Taiwan, 333 entry was removed and replaced with the Taoyuan City variant to reflect the corrected city designation.SummaryDifference0.0%

Stay in the know with updates to Savolitinib Combo in EGFRm+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page.